1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from. to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 1990;2021(398):957–80.
2. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, Yang J, Jiang Y, Xu X, Wang TD, Chen Y, Li Y, Yao L, Li D, Wang L, Shen X, Yin X, Liu W, Zhou X, Zhu B, Guo Z, Liu H, Chen X, Feng Y, Tian G, Gao X, Kario K, Cai J. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–79.
3. Deng Y, Bai J, Yang X, Liu W, Guo Z, Zhang J, Huang R, Yang X, Yu C, Yu J, Guo X, Wu H, Liu P, Zhang W, Cai J, et al. Achieved systolic blood pressure and cardiovascular outcomes in 60–80-year-old patients: the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial. Eur J Prev Cardiol. 2023;30:1017–27.
4. WHO. International drug monitoring: the role of national centres, report of a WHO meeting [Geneva, September 20-25 1971]. 1972. https://iris.who.int/handle/10665/40968. Accessed 30 Dec 2023
5. Tedla YG, Bautista LE. Drug side effect symptoms and adherence to antihypertensive medication. am J Hypertens. 2016;29:772–9.